Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors

Treatment of psoriatic arthritis with the oral Janus kinase inhibitor tofacitinib for 3 months was more effective than placebo in reducing joint manifestations, as determined by the American College of Rheumatology 20% response rate, but was associated with herpes infections.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2017-10, Vol.377 (16), p.1525-1536
Hauptverfasser:	Gladman, Dafna, Rigby, William, Azevedo, Valderilio F, Behrens, Frank, Blanco, Ricardo, Kaszuba, Andrzej, Kudlacz, Elizabeth, Wang, Cunshan, Menon, Sujatha, Hendrikx, Thijs, Kanik, Keith S
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Alanine Alanine transaminase Alanine Transaminase - blood Antirheumatic Agents - therapeutic use Arthritis Arthritis, Psoriatic - drug therapy Aspartate Aminotransferases - blood Cerebral infarction Cytokines Disability Evaluation Dose-Response Relationship, Drug Double-Blind Method Drug dosages Drug therapy Drug Therapy, Combination Enzyme inhibitors Female Herpes zoster Humans Inhibitor drugs Ischemia Janus kinase Janus Kinases - antagonists & inhibitors Male Middle Aged Myocardial infarction Patients Piperidines - administration & dosage Piperidines - adverse effects Piperidines - therapeutic use Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Psoriasis Psoriatic arthritis Pyrimidines - administration & dosage Pyrimidines - adverse effects Pyrimidines - therapeutic use Pyrroles - administration & dosage Pyrroles - adverse effects Pyrroles - therapeutic use TNF inhibitors Treatment Failure Tumor necrosis factor Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor necrosis factor-TNF
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Treatment of psoriatic arthritis with the oral Janus kinase inhibitor tofacitinib for 3 months was more effective than placebo in reducing joint manifestations, as determined by the American College of Rheumatology 20% response rate, but was associated with herpes infections.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1615977